Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern. This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.
Features include: Myxoid liposarcoma.
Biomarker and diagnostic research for myxoid liposarcoma has been reported in the published literature.
13 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and gene therapy. Pipeline includes 2 PHASE2, 9 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06083883](https://clinicaltrials.gov/study/NCT06083883) |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 4:05 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 |
PHASE1 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT07261657](https://clinicaltrials.gov/study/NCT07261657) | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | EARLY_PHASE1 | Seth Pollack | RECRUITING |
[NCT06843967](https://clinicaltrials.gov/study/NCT06843967) | A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | PHASE1 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT05492682](https://clinicaltrials.gov/study/NCT05492682) | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | PHASE1 | Valo Therapeutics Oy | RECRUITING |
[NCT04699292](https://clinicaltrials.gov/study/NCT04699292) | International Prospective Registry on Local Treatment Approaches in MLS | — | The Netherlands Cancer Institute | RECRUITING |
170 publications have been identified in PubMed for myxoid liposarcoma. Research spans Case Report / Case Series (32%), Review / Meta-Analysis (23%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 54 | 32% |
Research summaries | 39 | 23% |
Testing and diagnosis research | 22 | 13% |
Laboratory research | 19 | 11% |
Clinical study results | 13 | 8% |
Disease patterns and progression | 11 | 6% |
Other research | 8 | 5% |
New treatment approaches | 4 | 2% |
Aiba H (2026). [PMID: 42204032](https://pubmed.ncbi.nlm.nih.gov/42204032/). *Int J Clin Oncol*. [Epidemiology / Natural History]
Olivieri L (2026). [PMID: 41713724](https://pubmed.ncbi.nlm.nih.gov/41713724/). *J Vasc Interv Radiol*. [Clinical Trial Publication]
Chekaraou SM (2026). [PMID: 41938686](https://pubmed.ncbi.nlm.nih.gov/41938686/). *Pan Afr Med J*. [Case Report / Case Series]
Baird CAE (2026). [PMID: 41980504](https://pubmed.ncbi.nlm.nih.gov/41980504/). *Knee*. [Epidemiology / Natural History]
Zhang J (2026). [PMID: 41083372](https://pubmed.ncbi.nlm.nih.gov/41083372/). *Endocr J*. [Review / Meta-Analysis]
Hakimi T (2026). [PMID: 42267202](https://pubmed.ncbi.nlm.nih.gov/42267202/). *Oxf Med Case Reports*. [Case Report / Case Series]
Abrams HR (2026). [PMID: 41770651](https://pubmed.ncbi.nlm.nih.gov/41770651/). *Am J Clin Oncol*. [Clinical Trial Publication]
Hamed RR (2026). [PMID: 41782131](https://pubmed.ncbi.nlm.nih.gov/41782131/). *J Med Case Rep*. [Review / Meta-Analysis]
Liu J (2026). [PMID: 42192448](https://pubmed.ncbi.nlm.nih.gov/42192448/). *J Transl Med*. [Review / Meta-Analysis]
Beird HC (2026). [PMID: 42165630](https://pubmed.ncbi.nlm.nih.gov/42165630/). *Cancer Res Commun*. [Diagnostic / Biomarker]
AI-curated news mentioning myxoid liposarcoma
Updated May 16, 2026
A Phase 2 clinical trial, DOREMY, investigates the effects of dose reduction in preoperative radiotherapy for myxoid liposarcoma. The study aims to optimize treatment while maintaining efficacy in this rare cancer type.
A recent case report details myxoid liposarcoma of the sigmoid mesocolon, contributing to the understanding of this rare tumor type. The review of literature provides insights into its clinical presentation and management.